Eli Lilly: A Phase III Success with the New Weight Loss Pill Causes the Stock to Explode!
Reading Time: 1 minute
The market for GLP-1 products is expected to develop rapidly in the coming years. According to MarketsandMarkets, it could grow from $47.4 billion in 2024 to $471.1 billion in 2032. Major pharmaceutical companies like Novo Nordisk and Eli Lilly (LLY) are leading the way. Eli Lilly announced today strong study data on "Orforglipron." This is an oral GLP-1 medication. The hassle of injections is eliminated, and this is without compromising effectiveness. Consumers are likely to have increased interest in the product. "Orforglipron" is a GLP-1 product...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
